Dose-dependency and rate of decay of efficacy of resovist on MR images in a rat cirrhotic liver model

Investigative Radiology

Volumn 34, Issue 9, 1999, Pages 551-557

  Kato, Naoki ^a,c   Takahashi, Masaya ^d   Tsuji, Takashi ^a   Ihara, Shinya ^b   Brautigam, Matthias ^c   Miyazawa, Tomoaki ^a  

^a Nagoya University   (Japan)

^b Preclinical Development Department   (Japan)

^c Nihon Schering KK   (Japan)

^d HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cirrhosis; Contrast agent; Magnetic resonance; Rats; Resovist

Indexed keywords

NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; SUPERPARAMAGNETIC IRON OXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DOSE RESPONSE; HALF LIFE TIME; HISTOPATHOLOGY; LIVER CIRRHOSIS; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RADIATION DOSE; RAT; SIGNAL PROCESSING;

EID: 0032821256     PISSN: 00209996     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004424-199909000-00001     Document Type: Article

References (27)

1. Stark DD, Weissleder R, Elizondo G, et al. Superparamagnetic iron oxide: Clinical application as a contrast agent for MR imaging of the liver. Radiology 1988;168:297-301.
2. Hahn PF, Stark DD, Weissleder R, Elizondo G, Saini S, Ferrícci JT. Clinical application of Superparamagnetic iron oxide to MR imaging of tissue perfusion in vascular liver tumors. Radiology 1990; 174:361-366.
3. Schwartz LH, Seltzer SE, Tempany CMC, et al. Superparamagnetic iron oxide hepatic MR imaging: Efficacy and safety using conventional and fast spin-echo pulse sequences. J Magn Reson Imaging 1995;5:566.
4. Weissleder R, Stark DD, Engelstad BL, et al. Superparamagnetic iron oxide: Pharmacokinetics and toxicity. AJR 1989;152:167-173.
5. Lawaczeck R, Bauer H, Frenzel T, et al. Magnetic iron oxide particles coated with carboxydextran for parenteral administration and liver contrasting. Pre-clinical profile of SH U555A. Acta Radiol 1997; 38:584-597.
6. Kawamura Y, Endo K, Watanabe Y, et al. Use of magnetite particles as a contrast agent for MR imaging of the liver. Radiology 1990; 174:357-360.
7. Reimer P, Rummery EJ, Daldrup HE, et al. Clinical results with Resovist: A phase 2 clinical trial. Radiology 1995;195:489-496.
8. Fujita M, Yamamoto R, Fritz-Zieroth B, et al. Contrast enhancement with Gd-EOB-DTPA in MR imaging of hepatocellular carcinoma in mice: A comparison with Superparamagnetic iron oxide. J Magn Reson Imaging 1996;6:472-477.
9. Ishida T, Murakami T, Kato N, et al. Superparamagnetic iron oxide-enhanced magnetic resonance imaging of rat liver with hepatocellular carcinoma and benign hyperplastic nodule. Invest Radiol 1997;32:282-287.
10. Tanimoto A, Satoh Y, Yuasa Y, et al. Performance of Gd-EOB-DTPA and Superparamagnetic iron oxide particles in the detection of primary liver cancer: A comparative study by alternative free-response receiver operating characteristic analysis. J Magn Reson Imaging 1997;7:120-124.
11. Kopp AF, Laniado M, Damman F, et al. MR imaging of the liver with Resovist: Safety, efficacy, and pharmacodynamic properties. Radiology 1997;204:749-756.
12. Tanimoto A, Pouliquen D, Kreft BP, Stark DD. Effects of spatial distribution on proton relaxation enhancement by particulate iron oxide. J Magn Reson Imaging 1994;4:653-657.
13. Yablonskiy DA, Haacke EM. Theory of NMR signal behavior in magnetically inhomogeneous tissues: the static dephasing regime. Mag Reson Med 1994;32:749-763.
14. Halavaara JT, Lamminen AE, Bondestam S, Standertskjold-Nordenstam CG, Hamberg LM. Detection of focal liver lesions with superparamagnetic iron oxide: Value of STIR and SE imaging. J Comput Assist Tomogr 1994;18:897-904.
15. Bellin MF, Zaim S, Auberton E, et al. Liver metastases: Safety and efficacy of detection with superparamagnetic iron oxide in MR imaging. Radiology 1994;193:657-663.
16. Blakeborough A, Ward J, Wilson D, et al. Hepatic lesion detection at MR imaging: A comparative study with four sequences. Radiology 1997;203:759-765.
17. Caramella D, Jin XN, Mascalchi M, et al. Liver and spleen enhancement after intravenous injection of carboxydextran magnetite: Effect of dose, delay of imaging, and field strength in ex vivo model. MAGMA 1996;4:225-230.
18. Shimizu A, Kanisawa M. Experimental studies on hepatic cirrhosis and hepatocarcinogenesis. I. Production of hepatic cirrhosis by furfural administration. Acta Pathol Jpn 1986;36:1027-1038.
19. Elizondo G, Weissleder R, Stark DD, et al. Hepatic cirrhosis and hepatitis: MR imaging enhanced with superparamagnetic iron oxide. Radiology 1990;174:797-801.
20. Clement O, Frija G, Chambon C, et al. Liver tumors in cirrhosis: Experimental study with SPIO-enhanced MR imaging. Radiology 1991;180:31-36.
21. Yamashita Y, Yamamoto H, Hirai A, Yoshimatsu S, Baba Y, Takahashi M. MR imaging enhancement with superparamagnetic iron oxide in chronic liver disease: Influence of liver dysfunction and parenchymal pathology. Abdominal Imaging 1996;21:318-323.
22. Dashti H, Jepposson B, Hagerstrand I, et al. Thioacetamide- and carbon tetrachloride-induced liver cirrhosis. Eur Surg Res 1989;21: 83-91.
23. Duda SH, Laniado M, Kopp AF, et al. Superparamagnetic iron oxide: Detection of focal liver lesions at high-field-strength MR imaging. J Magn Reson Imaging 1994;4:309-314.
24. Kato N, Takahashi M, Ihara S, et al. Efficacy and safety of liver-specific MRI contrast agents in rats with hepatitis and cirrhosis. Acad Radiol 5 (suppl 1) 1998;S83-S85.
25. Hori N, Okanoue T, Sawa Y, et al. Hemodynamic characterization in experimental liver cirrhosis induced by thioacetamide administration. Dig Dis Sci 1993;2195-2202.
26. Kim T, Murakami T, Hasuike Y, et al. Experimental hepatic dysfunction: Evaluation by MRI with Gd-EOB-DTPA. J Magn Reson Imaging 1997;7:683-688.
27. Noda S, Masumi S, Moriyama M, et al. Population of hepatic macrophages and response of perfused liver platelet-activating factor during production of thioacetamide-induced cirrhosis in rats. Hepatology 1996;24:412-418.